08/23/2012
Reported online last week in Science Translational Medicine, researchers at MIT and Harvard used nanoparticles to demonstrate the nanoparticles that target a protein called ID4 can reduce ovarian cancer tumors in mice.
Researchers hope that this approach could help speed the development of new drugs. As new technology allows researchers to sequence cancer cell genomes, researchers are finding more and more gene mutations and deletions that may be therapeutic targets. This approach—using a mouse model to determine which ones are important—may help researchers prioritize which ones to focus drug development efforts on.
Click here for the abstract.
Related Topics

Ovarian Cancer Research Alliance Names Winners of Two Prizes in Recognition of Notable Research
Ovarian Cancer Research Alliance (OCRA), the largest global organization dedicated to advancing ovarian and related gynecologic cancer research, announced today the recipients of two prizes awarded for noteworthy work in … Continued

The Overview: January 2025
OCRA Joins Forces With Rivkin Center for Ovarian Cancer Research Ovarian Cancer Research Alliance (OCRA) has announced that the Rivkin Center for Ovarian Cancer Research will join with OCRA effective … Continued

How OCRA-Funded Research is Harnessing AI and Nanotechnology for Earlier Ovarian Cancer Detection, a Conversation with Clarke’s Closer Look
In a new interview with journalist Marcel Clarke for Clarke’s Closer Look, OCRA grantee Dr. Daniel Heller of Memorial Sloan Kettering Cancer Center discusses how his lab is utilizing artificial … Continued